Desvenlafaxine Pharmacology
Desvenlafaxine
antidepressant venlafaxine.it is a serotonin-norepinephrine reuptake inhibitor.
2.Distribution: Plasma protein binding: About 30%; independent of drug concentration
3.Metabolism: Hepatic via conjugation, lesser extent by oxidation via CYP3A4 isozyme.
4.Excretion: Excreted in urine
2.Nausea and vomiting
3.Dry mouth
4.Headache
5.Tinnitus
6.Insomnia
7.Abnormal dreams
8.Fatigue
9.Constipation
10.Diarrhea
11.Somnolence
12Decreased appetite
13.Irritability
14.Anxiety
15.Tremor
16.Paresthesia
17.Male sexual function disorders (e.g. Decreased libido, delayed ejaculation, erectile dysfunction)
18.Urinary hesitancy
19.Hyperhidrosis
20.Blurred vision
21.Mydriasis
22.Palpitations
23.Hypertension
24.Orthostatic hypotension
25.Dyslipidemia
26.Proteinuria
27.Abnormal liver function test.
28.Potentially Fatal: Serotonin syndrome or neuroleptic malignant syndrome-like reactions.
2.Concomitant/recent (within preceeding 14 days) use of MAOI.
3.Do not initiate MAOI at least 7 days after discontinuing Desvenlafaxine.
2.Serotonin syndrome or neuroleptic malignant syndrome (NMS) have occurred.
3.Gradually taper dose if discontinuing to reduce risk of withdrawal symptoms.
4.Caution in patients with pre-existing glaucoma, hypertension, cardiovascular, cerebrovascular, or lipid metabolism and seizure disorders.
5.May increase risk of bleeding.
6.May be associated with development of syndrome of inappropriate antidiuretic hormone (SIADH) and Hyponatraemia, elderly and patients who are taking diuretics or with volume depletion may be at greater risk
2.Depression with associated symptoms of anxiety.
3.Generalized anxiety disorder, and social anxiety disorder.
4.Treatment of adults with panic disorder.
2.May enhance adverse effects of other CNS depressants.
3.Concomitant use with alpha-/beta-agonists may enhance tachycardic and vasopressor effect.
4.Desvenlafaxine may increase concentration of CYP2D6 substrates (e.g. desipramine); decrease exposure of CYP3A4 substrates (e.g. midazolam).
5.CYP3A4 inhibitors (e.g. ketoconazole) may increase concentration of desvenlafaxine.
6.May enhance the antiplatelet effect of nonselective NSAIDs, aspirin; and anticoagulant effect of warfarin.
7.Potentially Fatal: Concurrent use with MAOIs may lead to fatal serotonin syndrome or NMS-like reactions. Do not use within at least 14 days of discontinuing MAOI treatment and start MAOI at least 7 days after stopping desvenlafaxine.
8.Increased risk of serotonin syndrome with sibutramine.
Management: Treatment is supportive and symptomatic. Activated charcoal may be administered. Induction of emesis is not recommended. Forced diuresis, dialysis
Home Delivery for Desvenlafaxine in Your City
Medicine India is just a publishing medium for medicine related information and does not provide services or sales of medicines including desvenlafaxine.
However, we do publish a comprehensive directory of Pharmacies, Chemists and Druggists in cities all over India. You can use this directory to find the medicine stores in your city (or area) that provide home delivery services for desvenlafaxine and other medicines and health products. Home delivery services for desvenlafaxine may be free or they may cost you depending on the pharmacy and the minimum order requirements. It would be best to get this clarified while placing the order.
Please be aware that you should take desvenlafaxine only if a doctor has recommended or prescribed it. Some or all pharmacies who provide a home delivery service for medicines might insist on a prescription for desvenlafaxine before they complete the sale. You can get this information while placing the order for desvenlafaxine with the pharmacy.
Desvenlafaxine is a generic medicine name and there are several brands available for it. Some of the brands for desvenlafaxine might be better known than desvenlafaxine itself. If the pharmacy that's willing to deliver medicines to your home doesn't have desvenlafaxine in stock, you can ask for one of the branded alternatives for desvenlafaxine.